Surfactant for pulmonary haemorrhage in neonates

Area of Science:

• Neonatal Medicine
• Respiratory Physiology
• Clinical Trials

Background:

• Pulmonary haemorrhage (PH) incidence has shifted from term to preterm infants with severe respiratory distress syndrome (RDS).
• Risk factors include prematurity, severe RDS, patent ductus arteriosus (PDA), and assisted ventilation.
• Surfactant therapy has shown promising results in case reports and uncontrolled studies for PH treatment.

Purpose of the Study:

• To evaluate the efficacy of surfactant treatment versus placebo or no intervention for neonatal pulmonary haemorrhage (PH).
• To assess the impact of surfactant on mortality and morbidities in neonates with PH.

Main Methods:

• Searched multiple databases (MEDLINE, EMBASE, CINAHL, etc.) and clinical trial registries up to February 2012.
• Included randomized or quasi-randomized controlled trials of surfactant for PH in intubated neonates (<37 weeks gestation).
• Planned meta-analysis using risk ratios and mean differences, with fixed-effect models and bias assessment.

Main Results:

• No randomized or quasi-randomized controlled trials evaluating surfactant for pulmonary haemorrhage (PH) were identified.
• Consequently, no conclusions regarding surfactant's efficacy in treating PH could be drawn from high-quality evidence.

Conclusions:

• The absence of randomized controlled trials (RCTs) prevents definitive conclusions on surfactant's effectiveness for neonatal PH.
• Promising results from observational studies warrant further high-quality RCTs to establish surfactant's role in PH treatment.